JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web browser. It makes web pages functional for specific purposes and if disabled for some reason, the content or the functionality of the web page can be limited or unavailable.

Saturday, March 22, 2025

What you need to know about the Delta variant

by

1322 days ago
20210808
FILE - In this March 29, 2021 file photo, a worker readies syringes with the Moderna COVID-19 vaccine in Metairie, La.

FILE - In this March 29, 2021 file photo, a worker readies syringes with the Moderna COVID-19 vaccine in Metairie, La.

Gerald Herbert

As the COVID-19 pan­dem­ic con­tin­ues across the world, pub­lic health of­fi­cials are watch­ing cer­tain coro­n­avirus mu­ta­tions and vari­ants that may be more con­ta­gious or dead­ly than the orig­i­nal strain. Virus­es con­stant­ly change to adapt and sur­vive, and vari­ants emerge when a strain has one or more mu­ta­tions that dif­fer from oth­ers.

The CDC and World Health Or­ga­ni­za­tion (WHO) mon­i­tor these vari­a­tions to find out if trans­mis­sion could lead to a surge in COVID-19 cas­es and deaths, as well as whether cur­rent vac­cines can pro­vide pro­tec­tion.

The US clas­si­fies them as ei­ther a “vari­ant of in­ter­est,” which may lead to out­breaks but isn’t wide­spread in the coun­try; a “vari­ant of con­cern,” which shows ev­i­dence of in­creased trans­mis­sion and more se­vere dis­ease; or a “vari­ant of high con­se­quence,” which makes vac­cines and treat­ments much less like­ly to work well.

So far, the US hasn’t clas­si­fied any coro­n­avirus vari­ants as “high con­se­quence,” but nu­mer­ous strains have been la­belled as “vari­ants of con­cern” that need to be fol­lowed close­ly.

In par­tic­u­lar, the Delta vari­ant has drawn fo­cused at­ten­tion dur­ing the past month due to a rapid in­crease in cas­es in sev­er­al coun­tries, in­clud­ing the US.

Here’s what you need to know about the Delta vari­ant

The Delta vari­ant, al­so known as B1.617.2, can spread more eas­i­ly, ac­cord­ing to the CDC. The strain has mu­ta­tions on the spike pro­tein that make it eas­i­er for it to in­fect hu­man cells.

That means peo­ple may be more con­ta­gious if they con­tract the virus and more eas­i­ly spread it to oth­ers. It is now the dom­i­nant strain in the US.

In fact, re­searchers have said that the Delta vari­ant is about 50 per cent more con­ta­gious than the Al­pha vari­ant, which was first iden­ti­fied in the UK, ac­cord­ing to The Wash­ing­ton Post. Al­pha, al­so known as B.1.1.7, was al­ready 50 per cent more con­ta­gious than the orig­i­nal coro­n­avirus first iden­ti­fied in Chi­na in 2019.

Pub­lic health ex­perts es­ti­mate that the av­er­age per­son who gets in­fect­ed with Delta spreads it to three or four oth­er peo­ple, as com­pared with one or two oth­er peo­ple through the orig­i­nal coro­n­avirus strain, ac­cord­ing to Yale Med­i­cine.

The Delta vari­ant may al­so be able to es­cape pro­tec­tion from vac­cines and some COVID-19 treat­ments, though stud­ies are still on­go­ing.

The Delta Plus vari­ant, al­so known as B.1.617.2.1 or AY.1, is con­sid­ered a “sub­vari­ant” of the Delta ver­sion, ac­cord­ing to CBS News.

It has a mu­ta­tion that al­lows the virus to bet­ter at­tack lung cells and po­ten­tial­ly es­cape vac­cines.

First iden­ti­fied in In­dia, Delta Plus has now been found in the US, UK, and near­ly a dozen oth­er coun­tries. In­dia has la­belled it a vari­ant of con­cern, but up to Ju­ly 21 the CDC and WHO haven’t.

The Delta vari­ant was first iden­ti­fied in In­dia in De­cem­ber 2020 and led to ma­jor out­breaks in the coun­try. It then spread rapid­ly and is now re­port­ed in 104 coun­tries, ac­cord­ing to a CDC track­er.

As of ear­ly Ju­ly, Delta has be­come the dom­i­nant form of the coro­n­avirus in the US, UK, Ger­many, and oth­er coun­tries. In the UK, for in­stance, the Delta vari­ant now makes up more than 97 per cent of new COVID-19 cas­es, ac­cord­ing to Pub­lic Health Eng­land.

What are the symp­toms of the Delta vari­ant?

The symp­toms are sim­i­lar to those seen with the orig­i­nal coro­n­avirus strain and oth­er vari­ants, in­clud­ing a per­sis­tent cough, headache, fever, and sore throat.

At the same time, COVID-19 pa­tients in the UK have re­port­ed that some symp­toms are slight­ly dif­fer­ent for Delta, ac­cord­ing to da­ta from the ZOE COVID Symp­tom Study. Cough and loss of smell seem to be less com­mon. Headache, sore throat, run­ny nose, and fever seem to be more com­mon.

Is the Delta vari­ant more dead­ly?

Sci­en­tists are still track­ing the da­ta to de­ter­mine how dead­ly it is. Based on hos­pi­tal­i­sa­tions in the UK, the Delta vari­ant does seem to be more like­ly to lead to hos­pi­tal­i­sa­tion and death, par­tic­u­lar­ly among un­vac­ci­nat­ed peo­ple, ac­cord­ing to a re­cent study pub­lished in The Lancet.

Peo­ple who haven’t been ful­ly vac­ci­nat­ed against COVID-19 are most at risk, Yale Med­i­cine re­port­ed.

In the US, com­mu­ni­ties with low vac­ci­na­tion rates have seen a jump in cas­es, par­tic­u­lar­ly in Mid­west and South­ern states such as Mis­souri and Arkansas. Out­breaks have al­so been found in Moun­tain states, such as Wyoming.

Kids and younger adults who haven’t been vac­ci­nat­ed may be sus­cep­ti­ble as well. In the UK, chil­dren and un­vac­ci­nat­ed adults un­der age 50 were 2.5 times more like­ly to be­come in­fect­ed with Delta, ac­cord­ing to a re­cent study pub­lished by Im­pe­r­i­al Col­lege Lon­don.

What does the Delta vari­ant mean for the vac­ci­nat­ed?

Sci­en­tists are look­ing at how the Delta vari­ant can cause break­through cas­es, or in­fec­tions among peo­ple who are ful­ly vac­ci­nat­ed. So far, they seem to be rare.

In a pre­lim­i­nary analy­sis, two dos­es of the Pfiz­er or Mod­er­na vac­cine ap­peared to be about 88 per cent ef­fec­tive against dis­ease and 96 per cent ef­fec­tive against hos­pi­tal­i­sa­tion with the Delta vari­ant, ac­cord­ing to Pub­lic Health Eng­land.

The As­traZeneca vac­cine, which has not been au­tho­rised for use in the US, was about 60 per cent ef­fec­tive against dis­ease and 93 per cent ef­fec­tive against hos­pi­tal­i­sa­tion.

Now vac­cine mak­ers are test­ing boost­er shots to find out if they can bet­ter pro­tect against the Delta vari­ant and oth­er vari­ants that emerge in com­ing months. Pfiz­er an­nounced that it will seek FDA au­tho­ri­sa­tion for a boost­er dose in Au­gust, ac­cord­ing to CNN.

Source—www.web­md.com


Related articles

Sponsored

Weather

PORT OF SPAIN WEATHER

Sponsored